This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.
Study Type
OBSERVATIONAL
Enrollment
314
None - observational study
Northwestern
Evanston, Illinois, United States
NOT_YET_RECRUITINGBrigham & Women's Hospital
Boston, Massachusetts, United States
NOT_YET_RECRUITINGTufts Medical Center
Medford, Massachusetts, United States
NOT_YET_RECRUITINGUniversity of Michigan
Ann Arbor, Michigan, United States
NOT_YET_RECRUITINGCleveland Clinic
Cleveland, Ohio, United States
NOT_YET_RECRUITINGUniversity of Virginia
Charlottesville, Virginia, United States
RECRUITINGUniversity Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
NOT_YET_RECRUITINGLondon Chest Hospital
London, United Kingdom
NOT_YET_RECRUITINGChange in % LGE mass
To assess the change in LGE extent from baseline over a minimum of 7 years of follow-up extent in HCM patients who would have been candidates for clinical trials of aficamten.
Time frame: From baseline over a minimum of 7 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.